Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2018 /
Highlights in early non-metastatic NSCLC and thoracic tumours

19th - 23rd Oct 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 26.10.18
Views: 1623

Dr Enriqueta Felip - Vall d'Hebron University Hospital (VHIO), Barcelona, Spain

Dr Felip speaks with ecancer at ESMO 2018 in Munich about research reported at the conference in early lung cancers.

She highlights research from Dr Wu Zhong on erlotinib for EGFRm NSCLC and a combination trial of anti-PD1 and anti-CTLA4 nivolumab and ipilimumab as showing promise.

The use of atezolizumab in 2nd line therapy, presented by Dr Jean-Louis Pujol, was ultimately ineffective, and Dr Felip highlights overall survival data from the PACIFIC trial as the most significant to clinicians daily practice.

ecancer's filming has been kindly supported by MSD through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation